EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China

Abstract

Authors

X. He S. Fu

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×